August 3, 2009
LONDON, OntarioNaringenin, the predominant citrus-derived flavonoid found in grapefruit, through its correction of many of the metabolic disturbances linked to insulin resistance, represents a promising therapeutic approach for metabolic syndrome, according to a published in the July issue of Diabetes. Mice fed a high-fat (western) diet become dyslipidemic, insulin and glucose intolerant, and obese. Four groups of mice (chow, western and western plus 1 percent or 3 percent, w/w naringenin) were fed ad libitum for four weeks. Very low-density lipoprotein (VLDL) production and parameters of insulin and glucose tolerance were determined. Researchers reported naringenin treatment of low-density lipoprotein receptor null (LDLR(-/-)) mice fed a western diet, corrected VLDL overproduction, ameliorated hepatic steatosis and attenuated dyslipidemia, without affecting caloric intake or fat absorption. Naringenin increased hepatic fatty-acid oxidation through a PPARgamma coactivator 1 alpha/PPARalpha-mediated transcription program; prevented SREBP1c-mediated lipogenesis in both liver and muscle by reducing fasting hyperinsulinemia; decreased hepatic cholesterol and cholesterol ester synthesis, reduced both VLDL-derived and endogenously synthesized fatty acid preventing muscle triglyceride accumulation; and improved overall insulin sensitivity and glucose tolerance.
You May Also Like
The ashwagandha root production process: Where tradition meets science – article part threeSep 21, 2023
Former FDA employees weigh in on gov’t shutdownSep 27, 2023
HerbalGram celebrates 40 years of bringing ancient herbal traditions back to life in AmericaSep 27, 2023
New science advances probiotics, milk fats and herbsSep 27, 2023